AbbVie Files a Form 8-K

PR Newswire/Les Echos/ 
AbbVie Files a Form 8-K 
NORTH CHICAGO, Ill., Jan. 2, 2013 -- AbbVie Inc. ("AbbVie") (NYSE / CHX /
Euronext Paris / SIX: ABBV) today informs its stockholders that it has filed a
Current Report on Form 8-K with the U.S. Securities and Exchange Commission
("SEC") on January 2, 2013, announcing the effectiveness of its separation and
distribution agreement with Abbott Laboratories. AbbVie is now an independent
public company trading under the symbol "ABBV" on the New York Stock Exchange,
NYSE Euronext Paris, the Chicago Stock Exchange and the SIX Swiss Exchange. 
AbbVie also announced in the Form 8-K that on December 31, 2012, the Board of
Directors of AbbVie expanded its size from three directors to nine directors,
and that AbbVie amended and restated its Certificate of Incorporation and
AbbVie makes available free of charge on its website, its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, reports filed
pursuant to Section 16 of the U.S. Securities Exchange Act of 1934 and
amendments to those reports filed with or furnished to the SEC as soon as
reasonably practicable after AbbVie electronically files these documents with,
or furnishes them to, the SEC. These documents are posted on AbbVie's website at 
The SEC maintains a website that contains reports, proxy statements and other
information regarding issuers that file electronically with the SEC. These
materials may be obtained electronically by accessing the SEC's home page at 
Copies of the above referenced information will also be made available, free of
charge, upon written request to AbbVie Inc., Investors Relations, 1 North
Waukegan Road, North Chicago, Illinois 60064, U.S.A.

SOURCE AbbVie Inc. 
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication. 
-0- Jan/03/2013 08:26 GMT
Press spacebar to pause and continue. Press esc to stop.